30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
In Appeal of Watts Constructors, LLC, the Armed Services Board of Contract Appeals (the “Board”) h...
Read More >
This blog is littered with posts talking about the various states that are intent on creating a Cali...
Read More >
Female Nurses Paid Less Than Less Experienced Male Counterpart, Federal Agency Charged - CASPER, W...
Read More >
The National Labor Relations Board (NLRB) - The NLRB issuing a Final Rule is just one part of the ...
Read More >
At an increasing rate, employers who hire STEM OPT students are being audited by U.S. Immigration an...
Read More >
Workers of Gig-Economy Platforms are Employees, Madrid’s Court of Justice Rules - Precedential Dec...
Read More >